Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer.
Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. Vervoort SJ, et al. Among authors: knight da. Cell. 2021 Jun 10;184(12):3143-3162.e32. doi: 10.1016/j.cell.2021.04.022. Epub 2021 May 17. Cell. 2021. PMID: 34004147 Free PMC article.
Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation.
Kong IY, Rimes JS, Light A, Todorovski I, Jones S, Morand E, Knight DA, Bergman YE, Hogg SJ, Falk H, Monahan BJ, Stupple PA, Street IP, Heinzel S, Bouillet P, Johnstone RW, Hodgkin PD, Vervoort SJ, Hawkins ED. Kong IY, et al. Among authors: knight da. Cell Rep. 2020 Oct 20;33(3):108290. doi: 10.1016/j.celrep.2020.108290. Cell Rep. 2020. PMID: 33086063 Free article.
Tumor immune evasion arises through loss of TNF sensitivity.
Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J. Kearney CJ, et al. Among authors: knight da. Sci Immunol. 2018 May 18;3(23):eaar3451. doi: 10.1126/sciimmunol.aar3451. Sci Immunol. 2018. PMID: 29776993
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW. Waibel M, et al. Among authors: knight da. Cell Rep. 2013 Nov 27;5(4):1047-59. doi: 10.1016/j.celrep.2013.10.038. Epub 2013 Nov 21. Cell Rep. 2013. PMID: 24268771 Free PMC article.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. Knight DA, et al. J Clin Invest. 2013 Mar;123(3):1371-81. doi: 10.1172/JCI66236. Epub 2013 Feb 1. J Clin Invest. 2013. PMID: 23454771 Free PMC article.
BRAF-targeted therapy and immune responses to melanoma.
Ngiow SF, Knight DA, Ribas A, McArthur GA, Smyth MJ. Ngiow SF, et al. Among authors: knight da. Oncoimmunology. 2013 Jun 1;2(6):e24462. doi: 10.4161/onci.24462. Epub 2013 May 9. Oncoimmunology. 2013. PMID: 23894707 Free PMC article.
264 results